Cargando…
Prostate cancer patient‐derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens
Patient‐derived organoids (PDOs) represent promising preclinical models in various tumor types. In the context of prostate cancer (PCa), however, their establishment has been hampered by poor success rates, which impedes their broad use for translational research applications. Along with the necessi...
Autores principales: | Servant, Raphaëlle, Garioni, Michele, Vlajnic, Tatjana, Blind, Melanie, Pueschel, Heike, Müller, David C, Zellweger, Tobias, Templeton, Arnoud J, Garofoli, Andrea, Maletti, Sina, Piscuoglio, Salvatore, Rubin, Mark A, Seifert, Helge, Rentsch, Cyrill A, Bubendorf, Lukas, Le Magnen, Clémentine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361965/ https://www.ncbi.nlm.nih.gov/pubmed/33934365 http://dx.doi.org/10.1002/path.5698 |
Ejemplares similares
-
Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer
por: Garioni, Michele, et al.
Publicado: (2023) -
Diagnostische und prädiktive Marker in der Harntraktzytologie
por: Vlajnic, Tatjana, et al.
Publicado: (2022) -
Urinary Calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer
por: Bausch, Kathrin, et al.
Publicado: (2019) -
Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer
por: Mengus, Chantal, et al.
Publicado: (2011) -
MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling
por: Offermann, Anne, et al.
Publicado: (2016)